Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891389 | 1.00 | TRPM8 (0.52) | TRPM8EPHX1P2RX4AAK1TRPV1 | |
| SCHEMBL18812466 | 0.88 | TRPM8 (0.38) | TRPM8AAK1HPGD | |
| SCHEMBL17923432 | 0.86 | TRPM8 (0.48) | TRPM8EPHX1P2RX4TRPV1ALDH1A1 | |
| SCHEMBL10155415 | 0.86 | TRPM8 (0.48) | TRPM8EPHX1P2RX4TRPV1ALDH1A1 | |
| SCHEMBL10155495 | 0.83 | TRPM8 (0.55) | TRPM8EPHX1P2RX4TRPV1ALDH1A1 | |
| SCHEMBL2628634 | 0.77 | TRPM8 (0.70) | TRPM8EPHX1TRPV1ALDH1A1HPGD | |
| SCHEMBL10155503 | 0.74 | TRPM8 (0.55) | TRPM8EPHX1P2RX4TRPV1ALDH1A1 | |
| SCHEMBL18662582 | 0.74 | TRPM8 (0.77) | TRPM8EPHX1P2RX4TRPV1 | |
| SCHEMBL10155499 | 0.73 | TRPM8 (0.48) | TRPM8EPHX1P2RX4ALDH1A1HPGD | |
| SCHEMBL10155490 | 0.73 | TRPM8 (0.64) | TRPM8EPHX1TRPV1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160338928-A1 | SKIN ENGAGING MEMBER COMPRISING A CYCLOHEXANECARBOXAMIDE DERIVATIVE | THE GILLETTE COMPANY LLC | 2016-11-24 | — | — | US | claimed |
| US-9974761-B2 | Medications for deposition on biological surfaces | THE PROCTER & GAMBLE COMPANY (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170119639-A1 | COMPOSITIONS FOR DEPOSITION ON BIOLOGICAL SURFACES | PROCTER & GAMBLE (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170079939-A1 | Medications For Deposition On Biological Surfaces | PROCTER & GAMBLE (US) | 2017-03-23 | — | — | US | disclosed |
| US-20160338928-A1 | SKIN ENGAGING MEMBER COMPRISING A CYCLOHEXANECARBOXAMIDE DERIVATIVE | THE GILLETTE COMPANY LLC | 2016-11-24 | — | — | US | disclosed |
| US-9492411-B2 | Medications for deposition on biological surfaces | THE PROCTER & GAMBLE COMPANY (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2510925-B1 | Small-Molecule modulators of TRP-P8 activity | DENDREON CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20150306050-A1 | Medications For Deposition On Biological Surfaces | THE PROCTER & GAMBLE COMPANY | 2015-10-29 | — | — | US | disclosed |
| US-20150307447-A1 | COMPOSITIONS FOR DEPOSITION ON BIOLOGICAL SURFACES | THE PROCTER & GAMBLE COMPANY | 2015-10-29 | — | — | US | disclosed |
| US-20120225871-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120083493-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2012-04-05 | — | — | US | disclosed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7741355-B2 | Small-molecule modulators of TRP-p8 activity | DENDREON CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741355-B2 | Small-molecule modulators of TRP-p8 activity | DENDREON CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| WO-2009067410-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306050-A1 | Medications For Deposition On Biological Surfaces | TAS2R30, TAS2R20, TAS2R10 | TRPM8 33/4885EPHX1 3588/4885P2RX4 684/4885 |
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | TRPC4, TRPC3, TRPC1 | TRPM8 7/4885EPHX1 2888/4885P2RX4 81/4885 |
| US-20170119639-A1 | COMPOSITIONS FOR DEPOSITION ON BIOLOGICAL SURFACES | CUTA, TAS2R40, TAS2R20 | TRPM8 54/4885EPHX1 3030/4885P2RX4 849/4885 |
| US-20170079939-A1 | Medications For Deposition On Biological Surfaces | TAS2R30, TAS2R20, TAS2R10 | TRPM8 33/4885EPHX1 3588/4885P2RX4 684/4885 |
| US-20150307447-A1 | COMPOSITIONS FOR DEPOSITION ON BIOLOGICAL SURFACES | CUTA, TAS2R40, TAS2R20 | TRPM8 54/4885EPHX1 3030/4885P2RX4 849/4885 |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | TRPM8 7/4885EPHX1 2888/4885P2RX4 81/4885 |
| US-20120225871-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | TRPM8 7/4885EPHX1 2888/4885P2RX4 81/4885 |
| US-20120083493-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | TRPM8 7/4885EPHX1 2888/4885P2RX4 81/4885 |
| US-20160338928-A1 | SKIN ENGAGING MEMBER COMPRISING A CYCLOHEXANECARBOXAMIDE DERIVATIVE | CUTA, TRPA1, TRPV1 | TRPM8 4/4885EPHX1 1683/4885P2RX4 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.